Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30808536 | 1.00 | LMNA (0.43) | LMNAPOLBCASP6RAB9ASMN1; SMN2 | |
| SCHEMBL23406185 | 0.91 | LMNA (0.52) | LMNAPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL22394636 | 0.88 | LMNA (0.45) | LMNAPOLBCASP6RAB9ASMN1; SMN2 | |
| SCHEMBL22394693 | 0.83 | RAB9A (0.50) | LMNARAB9AKMT2AALDH1A1RXRA | |
| SCHEMBL23406206 | 0.79 | LMNA (0.55) | LMNAPOLBRAB9ANPC1HPGD | |
| SCHEMBL23406183 | 0.77 | SRD5A2 (0.52) | LMNAPOLBRAB9AHPGDMAPT | |
| SCHEMBL9721182 | 0.74 | ALDH1A1 (0.62) | POLBSMN1; SMN2ALDH1A1SRD5A2 | |
| SCHEMBL22394730 | 0.74 | SRD5A2 (0.49) | LMNAPOLBGAAMAPTALDH1A1 | |
| SCHEMBL30808535 | 0.74 | SRD5A2 (0.49) | LMNAPOLBGAAMAPTALDH1A1 | |
| SCHEMBL22394754 | 0.74 | LMNA (0.52) | LMNARAB9ASMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574153-A2 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | University of Miami (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250145586-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | UNIVERSITY OF MIAMI | 2025-05-08 | — | — | US | disclosed |
| EP-3704103-B1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | UNIV MIAMI (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-111801322-B | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | 迈阿密大学 | 2024-03-15 | — | — | CN | disclosed |
| US-11926613-B2 | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | UNIVERSITY OF MIAMI (US) | 2024-03-12 | — | — | US | disclosed |
| US-20210163444-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | UNIVERSITY OF MIAMI | 2021-06-03 | — | — | US | disclosed |
| US-20210163444-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | UNIVERSITY OF MIAMI | 2021-06-03 | — | — | US | disclosed |
| CN-111801322-A | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | 迈阿密大学 | 2020-10-20 | — | — | CN | disclosed |
| EP-3704103-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | University of Miami (US) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163444-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | PNCK, PYGB, PMP22 | LMNA 3160/4885POLB 2207/4885CASP6 2689/4885 |
| US-11926613-B2 | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | PNCK, PYGB, PMP22 | LMNA 3160/4885POLB 2207/4885CASP6 2689/4885 |
| US-20250145586-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | MAP3K20, MAP4K2, MAP4K1 | LMNA 3318/4885POLB 2880/4885CASP6 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.